Tumor Microenvironment and Hemorheological Abnormalities

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 5, 2003, Pages 489-497

  Baronzio, Gianfranco ^b   Freitas, Isabel ^a   Kwaan, Hau C ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b ASl 1   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hemorheology; Hypoxia; Thrombosis; Tumor interstitial fluid; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; THROMBOCYTE ANTIBODY; TNP 740; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BLOOD CELL; BLOOD CLOTTING; BLOOD RHEOLOGY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMICAL COMPOSITION; ENDOTHELIUM CELL; HEMODYNAMICS; HUMAN; HYPOXIA; INTERSTITIAL FLUID; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); OXYGEN TENSION; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; TREATMENT OUTCOME; TUMOR CELL;

ANOXIA; EXTRACELLULAR FLUID; HEMORHEOLOGY; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 0242298635     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44557     Document Type: Review

References (81)

1. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 2002;299:676-680
2. Freitas I, Baronzio GF. Tumor hypoxia, reoxygenation and oxygenation strategies: possible role in photodynamic therapy. J Photochem Photobiol B 1991;11:3-30
3. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors, a review. Cancer Res 1989;49:6449-6465
4. Risau W. Mechanisms of angiogenesis. Nature 1997;386: 671-674
5. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001;61:795-798
6. Hlatky L, Hahnfeldt P, Tsionou C, et al. Vascular endothelial growth factor: environmental controls and effects in angiogenesis. Br J Cancer 1996;(suppl XII):s151-s156
7. Grunstein J, Roberts WG, Mathieu-Costello O, et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999;59:1592-1598
8. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;59:843-845
9. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462-468
10. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangigenesis as well as angiogenesis. J Exp Med 2002;196:1497-1506
11. Shurin MR, Lu L, Kalinsky P, et al. TH1/TH2 in cancer, transplantation and pregnancy. Semin Immunopathol 1999; 21:339-359
12. Vaupel P. Tumor blood flow. In: Molls M, Vaupel P, eds. Blood Perfusion and Microenvironment of Human Tumors. Berlin: Springer-Verlag; 2000:41-46
13. Vaupel P. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin Pädiatr 1997;209:243-249
14. + transport in the interstitial fluid. In: Goodie JA, Chadwick DJ, eds. The Tumor Microenvironment: Causes and Consequences of Hypoxia and Acidity. Novartis Foundation Symposium 2001. New York: John Wiley; 2001:46-67
15. Asby BS, Cantab MB. pH studies in human malignant tumors. Lancet 1996;2:312-315
16. Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltora KZ. The contribution of proangiogenic factors to the progression of malignant disease. Surg Oncol Clin N Am 2001;10:339-356
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
18. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancer and their metastases. Cancer Res 1999;59:5830-5835
19. Minet E, Mottet D, Roland I, et al. Hypoxia-induced activation of HIF-1: role of HIF-1 alpha-Hsp 90 interaction. FEBS Lett 1999;460:251-256
20. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845
21. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001;7:345-350
22. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649-1660
23. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29(suppl 16):10-14
24. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132
25. Konerding MA, Malkusch W, Klaptor B, et al. Evidence for characteristic vascular patterns in solid tumors: quantitative studies using corrosion casts. Br J Cancer 1999;80:724-732
26. Konerding MA, Steiberg F, van Ackern C, et al. Vascular patterns of tumors: Scanning and transmission electron microscopic studies on human xenografts. Strahlenther Onkol 1992; 168:444-452
27. Gullino PM. The internal milieu of tumors. Prog Exp Tumor Res 1966;8:1-25
28. Gullino PM. Extracellular compartments of solid tumors. In: Beckert FB, ed. Cancer, a Comprehensive Treatise. Vol. 3, Biology of Tumors: Cellular Biology and Growth. New York: Plenum; 1975:327-354
29. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380
30. Feng D, Nagy JA, Pyne K, et al. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 1999;6:23-44
31. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305-326
32. Freitas I, Baronzio GF, Bono B, et al. Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor. Anticancer Res 1997;17:165-172
33. Jain RK. Determinants of tumor blood flow: A review. Cancer Res 1988;48:2641-2658
34. Baronzio GF, Galante F, Gramaglia A, et al. Tumor microcirculation and its significance in therapy: possible role of omega-3 fatty acids as theological modifiers. Med Hypotheses 1998;50:175-182
35. Tamsmaa JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starlings law of capillary hemodynamics revisited. Ann Oncol 2001;12:1353-1357
36. Renkin E. Some consequences of capillary permeability to macromolecules: Starling's hypothesis reconsidered. Am J Physiol 1986;250:H706-H710
37. Bates DO, Hillman NJ, Williams B, et al. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 1989;49:3506-3512
38. Sevick EM, Jain R. Viscous resistance to blood flow in solid tumors: effect of hematocrit and intratumor viscosity. Cancer Res 1989;49:3513-3519
39. Freitas I, Baronzio GF, Bertone V, et al. Stroma formation in Ehrlich carcinoma. I. Oedema phase. A mitosis burst as an index of physiological reoxygenation? Anticancer Res 1991; 11:569-578
40. Freitas I, Bono B, Bertone V, et al. Characterization of the metabolism of perinecrotic cells in solid tumors by enzyme histochemistry. Anticancer Res 1996;16:1491-1502
41. Cicala C, Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sci 1998;62:1817-1824
42. Sylven B, Bois I. Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. Cancer Res 1960;20:831-834
43. Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol 2000;17:869-879
44. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-6694
45. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992;52:5110-5114
46. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-266
47. Jain RK. Therapeutic implications of tumor physiology. Curr Opin Oncol 1991;3:1105-1108
48. Stoher EA, Boucher Y, Stangasinger M, Jain R. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-4255
49. Wiig H, Aukland K, Tenstad O. Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. Am J Physiol Heart Circ Physiol 2003;284:H416-H424
50. Baronzio G, Freitas I, Griffini P, et al. Omega-3 fatty acids can improve radioresponse modifying tumor interstitial pressure, blood rheology and membrane peroxidability. Anticancer Res 1994;14:1145-1154
51. Stoltz JF, Singh M, Riha P. Microrheological parameters. In: Stoltz JF, Singh M, Riha P, eds. Hemorheology in Practice. Amsterdam: IOS Press; 1999:27-53
52. Yan S-F, Mackman N, Kisiel W, et al. Hypoxia/hypoemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Artherioscler Thromb Vasc Biol 1999;1:2029-2035
53. Browder T, Folkman J, Pirie-Sheperd S. The hemostatic system as regulator of angiogenesis. J Biochem 2000;275:1521-1524
54. Fernandez PM, Rickles F. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002;9:401-406
55. Ruf W, Mueller B. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996;3:379-384
56. Verheul HM, Hoekman K, Lupu F, van der Valk P, Brotterman HJ. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166-170
57. Verheul HM, Jorna AS, Hoekman K, et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96:4216-4221
58. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000;96:3772-3778
59. Lee T-H, Avraham H, Lee SH, et al. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002;277:10445-10451
60. Kadambi A, Moutacarreira C, Cook Y, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001;61:2404-2408
61. Heil M, Clauss M, Suzuki K, et al. Vascular endothelial growth factor - VEGF stimulates monocytes migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 2000;79:850-857
62. Griffioen AW, Tromp SC, Hillen HFP. Angiogenesis modulates the tumor immune response. Int J Exp Pathol 1998;79: 363-368
63. Koehne P, Strauss W, Schindler SE, et al. Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets. Am J Physiol Heart Circ Physiol 2000;279:H817-824
64. Michiels C, Arnould T, Remade J. Endothelial cell response to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000;1497:1-10
65. Salven P, Orfana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999;5:487-491
66. Tietjen GW, Chien S, Scholz P, et al. Changes in blood viscosity and plasma proteins in carcinoma. J Surg Oncol 1977; 9:53-59
67. von Tempelhoff GF, Heilman L, Hommel G, et al. Hyperviscosity syndrome in patients with ovarian carcinoma. Cancer 1998;82:1104-1111
68. Kwaan H, Gordon L. Thrombotic microangiopathy in the cancer patient. Acta Haematol 2001;106:52-56
69. Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000;102:199-209
70. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001;7:1194-1201
71. Cines DB, Pollack ES, Buck CA, et al. Endothelial cells in physiology and in pathophysiology of vascular disorders. Blood 1998;91:3527-3561
72. Santos MT, Valles J, Aznar J. Cell-cell interaction in thrombosis: modulation of platelet function and possibilities of pharmacological control with aspirin. Turk J Haematol 2002;19:103-111
73. Karmali RA. Eicosanoids in neoplasia. Prev Med 1987;16: 493-502
74. Bockman RS. Prostaglandins in cancer: a review. Cancer Invest 1983;1:485-493
75. Ten VS, Pinsky D. Endothelial response to hypoxia: physiological adaptation and pathologic dysfunction. Curr Opin Crit Care 2002;8:242-250
76. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-3378
77. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61: 2413-2418
78. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-2934
79. Teicher BA, Holden SA, Ara G, et al. Influence of antiangiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 1995;61:732-737
80. Roca C, Primo L. Hyperthermia and angiogenesis: results and perspectives. In: Barongio GF, ed. Hyperthermia in Cancer Treatment: Locoregional Radiofrequency Hyperthermia, Interstitial and Perfusional Hyperthermia. Georgetown, TX: Landes Bioscience Publisher; 2004: (in press)
81. Schmitt O, Schubert C, Feyerabend T, et al. Preferential topography of proteins regulating vascularization and apoptosis in a MX1 xenotrasplant after treatment with hypoxia, hyperthermia, isofosfamide, and irradiation. Am J Clin Oncol 2002;25:325-336 497